GSA Capital Partners’s Zevra Therapeutics ZVRA Stock Holding History

GSA Capital Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$331K	Buy	+23,104	New	+$257K	0.02%	1244
2025 Q4	–	Sell	-54,397	Closed	-$517K	–	2152
2025 Q3	$517K	Buy	+54,397	New	+$546K	0.04%	830
2022 Q4	–	Sell	-20,220	Closed	-$126K	–	1957
2022 Q3	$126K	Buy	20,220 +3,792	+23%	+$21.5K	0.02%	1328
2022 Q2	$73K	Sell	16,428 -67,524	-80%	-$308K	0.01%	1258
2022 Q1	$422K	Buy	+83,952	New	+$534K	0.06%	652

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GSA Capital Partners's ZVRA Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 23,104 shares worth $331K. The stake represents 0.02% of the portfolio and ranks #1244 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in ZVRA as recently as Q3 2025.

GSA Capital Partners first reported a position in ZVRA in Q1 2022 and has held it in 5 quarters since. The position peaked at $517K in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

GSA Capital Partners held 23,104 shares of Zevra Therapeutics worth $331K as of Q2 2026.
Zevra Therapeutics was a new GSA Capital Partners position in Q2 2026.
Zevra Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1244 holding.
GSA Capital Partners first reported a position in Zevra Therapeutics in Q1 2022 and has held it in 5 quarters since.
GSA Capital Partners's Zevra Therapeutics position peaked at $517K in Q3 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.